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Case 
report
Abstract
Lynch syndrome (LS) is the most common hereditary syndrome 
that predisposes patients to colorectal cancer, and it accounts 
for 2–5% of the total burden of colorectal cancer. We report 
a case of a 61-year-old female affected by Lynch syndrome 
who underwent multiple adenocarcinoma resections, studied 
by F18-FDG-PET/CT for 5 years. This case report suggests 
a potential role of F18-FDG-PET/CT in the evaluation of patients 
affected by Lynch syndrome.
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Introduction
Lynch syndrome (LS) is the most common hereditary syn-
drome that predisposes patients to colorectal cancer, and it ac-
counts for 2–5% of the total burden of colorectal cancer [1]. Since 
the identification of mismatch repair mutations in this syndrome, 
it has become known as Lynch syndrome and is characterized 
by germline mutation in a mismatch repair gene, most commonly 
MLH1, MSH2, or MSH6 [2]. It is now quite common to identify 
a germline mutation in one of the mismatch repair genes. It 
is characterised by an autosomal dominant inheritance pattern, 
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right-sided colonic cancer predilection, earlier average age of 
onset of colorectal cancer than in the general population, ac-
celerated carcinogenesis, high risk of additional colorectal can-
cers, and increased risk of malignant disease at other sites like 
the pancreas, upper uroepithelial tract, endometrium, ovary, 
brain (Turcot’s syndrome variant of LS), stomach, small bowel, 
hepatobiliary tract [2], and increased survival from colorectal 
cancer. Once a high-risk individual is recognized, management 
focuses primarily on strategies for risk reduction. Colonoscopic 
screening has been shown to significantly improve survival 
among carriers of a mutation associated with LS. Recommenda-
tions for at-risk members of families with LS include screening 
colonoscopy, endometrial sampling, transvaginal ultrasound, and 
in selected cases prophylactic colon and ovary or uterine surgery 
[3]. Surgery is the mainstay of treatment and can be prophylactic 
or therapeutic with curative or palliative intent. The type and extent 
of surgical resection is influenced by the effectiveness of, and 
patient compliance with, available surveillance strategies. There 
are no guidelines regarding the timing of surgery. Colectomy 
is recommended for patients with Lynch syndrome who have 
colorectal cancer, but the choice of procedure remains con-
troversial as surgical options include a total proctocolectomy 
(TPC) with permanent ileostomy, a total proctocolectomy with 
ileal pouch anal anastomosis (IPAA), or a subtotal colectomy 
with ileorectal anastomosis (IRA) [4]. 
Case report
We report the case of a 61-year-old female affected by LS 
studied by F18-FDG-PET/CT for 5 years. The patient underwent 
hysteoannessiectomy for an ovarian cancer in 1989, right hemi-
colectomy for adenocarcinoma in 1991, and another resection 
of transverse colon and part of the descending colon because 
of a disease relapse. In 2005 the patient developed an ad-
enocarcinoma of the rectum and underwent extended surgical 
resection of the remnant colon and rectum with permanent 
ileostomy; a subsequent diagnosis of LS was given. In 2006 
an endoscopic examination revealed an infiltrative duodenal 
lesion, and the patient underwent an F18-FDG-PET/CT that 
confirmed this finding (Figure 1-A1). A resection of the head 
of the pancreas and duodenum was performed and two PET 
studies during 2007 remained negative (Figure 1-A2; Figure 
1-A3). In 2008, after a rising value of CA19.9 marker, a new 
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F18-FDG-PET/CT was performed revealing pathologic uptake at 
a solid mesenteric lesion, just ahead of the right ureter (Figure 
1-A4). Chemotherapy was started, and after two cycles another 
PET study revealed no significant uptake reduction (Figure 
1-A5). At the beginning of 2009 another PET study documented 
disease progression at the end of chemotherapy at the same 
site (Figure 1-A6); on the basis of these findings, radiotherapy 
was performed with moderate effect in terms of uptake reduction 
in the middle of 2009 (Figure 1-A7), but, unfortunately, at the 
end of 2009 another PET study documented a slight increase 
of pathologic uptake at mesenteric lesion (Figure 1-A8) and 
CA19.9 elevation; at the beginning of 2010 significant disease 
progression in terms of higher uptake, a new mesenteric lesion 
near the previous one, and significant CA19.9 elevation were 
documented (Figure 1-A9). 
Discussion
The role of F18-FDG-PET/CT in oncologic imaging is well 
established; it has gained widespread acceptance as a diag-
nostic tool in oncology and is an increasingly important imaging 
test [5]. Numerous reports are available in literature about the 
usefulness and diagnostic role of F18-FDG-PET/CT in evalu-
ating pancreatic, endometrial, gastro-intestinal, and ovarian 
malignancies [6–9]; moreover, current evidence suggests that 
F18-FDG-PET/CT has an established role as a routine component 
of colorectal cancer (CRC) patient management in the detection 
of recurrent [10, 11] or residual disease and preoperative assess-
ment prior to metastasectomy. It is likely that further evidence will 
support the emerging roles in the staging, radiotherapy treatment 
planning, and assessment of treatment response both for primary 
tumours and metastases [12, 13]. This evidence suggests that 
F18-FDG-PET/CT could be considered an imaging tool able to 
usefully evaluate all the organs possibly affected by malignan-
cies in LS because of their hypermetabolic behaviour. To our 
knowledge there are no reports in literature about LS evaluation 
using F18-FDG-PET/CT, and this case report reveals how PET 
studies could be useful in evaluating this kind of patient both 
in terms of staging/restaging and therapy efficacy monitor-
ing, possibly modifying and guiding clinical management and 
therapeutic decision making. In conclusion, a potential role of 
F18-FDG-PET/CT in the evaluation of patients affected by LS 
should be considered despite the fact that wider studies are 
needed to definitively confirm this insight.
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